vs
CareDx, Inc.（CDNA）与CANTALOUPE, INC.（CTLP）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是CANTALOUPE, INC.的1.5倍（$117.7M vs $78.7M），CareDx, Inc.净利率更高（2.4% vs -0.1%，领先2.5%），CareDx, Inc.同比增速更快（39.0% vs 6.8%），CareDx, Inc.自由现金流更多（$514.0K vs $-614.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs 7.7%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
CDNA vs CTLP — 直观对比
营收规模更大
CDNA
是对方的1.5倍
$78.7M
营收增速更快
CDNA
高出32.2%
6.8%
净利率更高
CDNA
高出2.5%
-0.1%
自由现金流更多
CDNA
多$1.1M
$-614.0K
两年增速更快
CDNA
近两年复合增速
7.7%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $78.7M |
| 净利润 | $2.8M | $-70.0K |
| 毛利率 | — | — |
| 营业利润率 | 1.0% | 2.0% |
| 净利率 | 2.4% | -0.1% |
| 营收同比 | 39.0% | 6.8% |
| 净利润同比 | — | -101.4% |
| 每股收益（稀释后） | $0.05 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNACTLP
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $78.7M | ||
| Q3 25 | $100.1M | $80.9M | ||
| Q2 25 | $86.7M | $82.6M | ||
| Q1 25 | $84.7M | $75.4M | ||
| Q4 24 | $86.6M | $73.7M | ||
| Q3 24 | $82.9M | $70.8M | ||
| Q2 24 | $92.3M | $72.7M |
净利润CDNACTLP
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-70.0K | ||
| Q3 25 | $1.7M | $-919.0K | ||
| Q2 25 | $-8.6M | $6.8M | ||
| Q1 25 | $-10.4M | $49.2M | ||
| Q4 24 | $87.7M | $5.0M | ||
| Q3 24 | $-10.6M | $3.6M | ||
| Q2 24 | $-4.6M | $2.2M |
营业利润率CDNACTLP
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 2.0% | ||
| Q3 25 | -0.2% | 2.0% | ||
| Q2 25 | -12.8% | 6.3% | ||
| Q1 25 | -15.8% | 9.1% | ||
| Q4 24 | 97.5% | 8.4% | ||
| Q3 24 | -16.6% | 5.8% | ||
| Q2 24 | -7.9% | 4.9% |
净利率CDNACTLP
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -0.1% | ||
| Q3 25 | 1.7% | -1.1% | ||
| Q2 25 | -9.9% | 8.3% | ||
| Q1 25 | -12.2% | 65.2% | ||
| Q4 24 | 101.3% | 6.7% | ||
| Q3 24 | -12.8% | 5.0% | ||
| Q2 24 | -5.0% | 3.0% |
每股收益（稀释后）CDNACTLP
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.00 | ||
| Q3 25 | $0.03 | $-0.02 | ||
| Q2 25 | $-0.16 | $0.10 | ||
| Q1 25 | $-0.19 | $0.65 | ||
| Q4 24 | $1.60 | $0.07 | ||
| Q3 24 | $-0.20 | $0.04 | ||
| Q2 24 | $-0.09 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $53.0M |
| 总债务越低越好 | — | $37.7M |
| 股东权益账面价值 | — | $252.5M |
| 总资产 | $411.1M | $381.9M |
| 负债/权益比越低杠杆越低 | — | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资CDNACTLP
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $53.0M | ||
| Q3 25 | $194.2M | $55.0M | ||
| Q2 25 | $186.3M | $51.1M | ||
| Q1 25 | $230.9M | $46.3M | ||
| Q4 24 | $260.7M | $27.7M | ||
| Q3 24 | $240.9M | $33.1M | ||
| Q2 24 | $228.9M | $58.9M |
总债务CDNACTLP
| Q1 26 | — | — | ||
| Q4 25 | — | $37.7M | ||
| Q3 25 | — | $38.3M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | $0 | $37.3M | ||
| Q2 24 | $0 | $37.5M |
股东权益CDNACTLP
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $252.5M | ||
| Q3 25 | $311.1M | $251.8M | ||
| Q2 25 | $327.4M | $251.0M | ||
| Q1 25 | $379.3M | $240.7M | ||
| Q4 24 | $378.4M | $190.1M | ||
| Q3 24 | $273.2M | $186.2M | ||
| Q2 24 | $264.7M | $181.7M |
总资产CDNACTLP
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $381.9M | ||
| Q3 25 | $432.3M | $389.5M | ||
| Q2 25 | $444.3M | $381.9M | ||
| Q1 25 | $489.6M | $370.5M | ||
| Q4 24 | $491.1M | $303.0M | ||
| Q3 24 | $477.0M | $312.1M | ||
| Q2 24 | $466.8M | $335.6M |
负债/权益比CDNACTLP
| Q1 26 | — | — | ||
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | 0.00× | 0.20× | ||
| Q2 24 | 0.00× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $3.1M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $-614.0K |
| 自由现金流率自由现金流/营收 | 0.4% | -0.8% |
| 资本支出强度资本支出/营收 | — | 4.8% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $25.8M |
8季度趋势，按日历期对齐
经营现金流CDNACTLP
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $3.1M | ||
| Q3 25 | $37.4M | $7.0M | ||
| Q2 25 | $9.9M | $9.4M | ||
| Q1 25 | $-26.6M | $22.4M | ||
| Q4 24 | $21.9M | $522.0K | ||
| Q3 24 | $12.5M | $-12.0M | ||
| Q2 24 | $18.9M | $14.3M |
自由现金流CDNACTLP
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $-614.0K | ||
| Q3 25 | — | $3.5M | ||
| Q2 25 | — | $4.3M | ||
| Q1 25 | — | $18.6M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $-15.8M | ||
| Q2 24 | — | $8.5M |
自由现金流率CDNACTLP
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | -0.8% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 24.6% | ||
| Q4 24 | — | -5.1% | ||
| Q3 24 | — | -22.3% | ||
| Q2 24 | — | 11.7% |
资本支出强度CDNACTLP
| Q1 26 | — | — | ||
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 7.9% |
现金转化率CDNACTLP
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | 1.38× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | 0.25× | 0.10× | ||
| Q3 24 | — | -3.36× | ||
| Q2 24 | — | 6.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
